thebench.bio #1 Ecosystem for the Bio-Tech Industry

Research Daily Summary

Research Daily Summary: What Happened on November 11, 2026

Waist measures sharpen obesity risk classification in large study

Other research restored signaling in ALS-affected neurons, mapped receptor function and proposed an imaging measure for lung fibrosis.

  • Updated
  • Read from 4 articles, 2 publications
  • P

Today in brief

An analysis of 844,108 adults found that adding waist measures to BMI better distinguished obesity-related mortality risk than BMI alone.1 Researchers restored signaling in human neurons by correcting abnormal UNC13A RNA processing, and mapped functions across more than 7,500 receptor variants with a separate method.23

Waist measures improved obesity risk classification

An international analysis of 844,108 adults found that an obesity classification combining waist circumference and waist-to-height ratio with BMI tracked mortality risk better than BMI alone.1 Against the expanded definition, BMI alone overcounted obesity by up to 3.1% and missed cases by up to 8.6%.1

The expanded criteria raised estimated obesity prevalence by up to 7.4%. They classified 22.7% to 31.3% of the group as having clinical obesity.1 Clinical obesity was associated with 69% greater mortality risk than having neither obesity nor organ dysfunction. The increase for preclinical obesity was 19%.1 BMI-defined obesity alone was not associated with higher mortality in the study.1

The proposed approach defines clinical obesity through illness or organ dysfunction, while preclinical obesity involves excess body fat without those effects.1 Study author Francesco Rubino said the findings support treating clinical obesity as active disease and tailoring preventive care for people with preclinical obesity to their individual risk.1

Also worth knowing

  • Researchers used CRISPR-Cas9 editing and splice-switching antisense oligonucleotides to correct abnormal UNC13A RNA processing, restoring protein production and synaptic signaling in human neurons. The experiments did not test whether treatment slows ALS progression. Trace Neuroscience's UNC13A-targeting drug TRCN-1023 is in a Phase I/II trial.2

  • GPCR-MAPS measured activation and other functions across more than 7,500 variants of the β2 adrenergic receptor. The maps revealed a core activation network and several allosteric pockets that the researchers say could inform precision drug design.3

  • P

    Qureight published a peer-reviewed paper proposing quantitative high-resolution computed tomography to measure lung fibrosis in antifibrotic trials, potentially alongside lung-function testing. The authors say more evidence is needed before the measure could serve as a surrogate endpoint.4

Also published